X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Dengusiil is a tetravalent live attenuated dengue vaccine, which is being developed for the treatment of dengue.
Lead Product(s): Live Attenuated Tetravalent Dengue Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Dengusiil
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2024
Details:
Through the agreement, the companies will concentrate on scaling up the manufacture of BCG for use in combination with Anktiva (Nogapendekin Alfa Inbakicept) to treat non-muscle invasive bladder cancer.
Lead Product(s): Nogapendekin Alfa Inbakicept,Recombinant Bacillus Calmette-Guerin
Therapeutic Area: Oncology Product Name: Anktiva
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: ImmunityBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 02, 2024
Details:
Covovax (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
Covovax (NVX-COV2373), is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization and is seeking inclusion of covovax on CoWIN as heterologous booster dose for adults.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
Proceeds from the financing will support the clinical development of CodaVax™-RSV, an intranasal, live-attenuated vaccine candidate, for the prevention of respiratory syncytial virus (RSV) disease.
Lead Product(s): CodaVax-RSV
Therapeutic Area: Infections and Infectious Diseases Product Name: CodaVax-RSV
Highest Development Status: Phase IProduct Type: Vaccine
Recipient: Codagenix
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing February 15, 2023
Details:
India’s first indigenously developed Quadrivalent Human Papillomavirus vaccine (qHPV) ‘CERVAVAC’ is an outcome of a partnership between Serum Institute Of India (SII), Department of Biotechnology and the BIRAC, along with the Bill and Melinda Gates Foundation.
Lead Product(s): Capsid L1 Virus-like Particle
Therapeutic Area: Infections and Infectious Diseases Product Name: Cervavac
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
Covovax (NVX-CoV2373) is a protein-based vaccine engineered from the genetic sequence of the first strain of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
Details:
Covovax (NVX-COV2373) is a spike protein nanoparticle vaccine, manufactured through technology transfer from Novavax. It has been approved for marketing authorization as a booster dose for adults who have been administered two doses of covishield or covaxin by the DCGI.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2023
Details:
Covovax (NVX-COV2373), is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorization.
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2023
Details:
Covovax (NVX-CoV2373), is manufactured through technology transfer from Novavax. It has been approved by the European Medicines Agency for conditional marketing authorisation.
Lead Product(s): NVX-CoV2373
Therapeutic Area: Infections and Infectious Diseases Product Name: Covovax
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
